Hormonal Therapy Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

• News
• Research
• Blogs
• Podcasts
• Video
• Funding
• Clinical Trials
• Forums

Study of LY3484356 Versus Hormone Therapy, in Participants With Estrogen Receptor Positive (ER+), Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Breast Cancer
Conditions:   Breast Neoplasms;   Neoplasm Metastasis Interventions:   Drug: LY3484356;   Drug: Exemestane;   Drug: Fulvestrant Sponsor:   Eli Lilly and Company Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 23, 2021 Category: Research Source Type: clinical trials